Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26842626 | 0.95 | LMNA (0.40) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL22845199 | 0.93 | LMNA (0.37) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL24173421 | 0.93 | ALDH1A1 (0.36) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL22845209 | 0.93 | MAPT (0.42) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL26842658 | 0.88 | MAPT (0.35) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL22845425 | 0.88 | MTHFD2 (0.33) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL22845368 | 0.87 | PREP (0.40) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL24483838 | 0.87 | HDAC1 (0.35) | LMNAMAPTALDH1A1GAAMTHFD2 | |
| SCHEMBL22845327 | 0.86 | TACR3 (0.40) | LMNAMAPTALDH1A1GAAHTT | |
| SCHEMBL22845213 | 0.86 | MTHFD2 (0.43) | LMNAMAPTALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | LMNA 1680/4885MAPT 651/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.